

1           **Cross-cultural translation and psychometric validation of the**  
2           **French version of the Fear-Avoidance Components Scale (FACS)**

3   **Arnaud Duport<sup>1,2</sup>, Sonia Bédard<sup>3-4</sup>, Catherine Raynauld<sup>3-4</sup>, Martine Bordeleau<sup>2</sup>, Randy Neblett<sup>5</sup>,**  
4   **Frédéric Balg<sup>3-4</sup>, Hervé Devanne<sup>1</sup>, Guillaume Léonard<sup>2,3\*</sup>**

5   <sup>1</sup>Univ. Littoral Côte d’Opale, Univ. Artois, Univ. Lille, ULR 7369 - URePSSS - Unité de Recherche  
6   Pluridisciplinaire Sport Santé Société, F-62100 Calais, France

7   <sup>2</sup>Research Center on Aging, CIUSSS de l’Estrie-CHUS, 1036 rue Belvédère Sud, Sherbrooke, Qc J1H  
8   4C4, Canada

9   <sup>3</sup>Centre de recherche du CHUS, École de réadaptation, Faculté de médecine et des sciences de la santé,  
10   Université de Sherbrooke 3001, 12e Avenue Nord, Sherbrooke, Qc, Canada, J1H 5N4

11   <sup>4</sup>Surgery department, Orthopedic service, Université de Sherbrooke, Qc, Canada

12   <sup>5</sup>PRIDE Research Foundation, Dallas, TX, USA

13   **\*Correspondence:**

14   Guillaume Léonard

15   [guillaume.leonard2@usherbrooke.ca](mailto:guillaume.leonard2@usherbrooke.ca)

16   **Keywords: Fear avoidance, Fear-avoidance Components Scale, French version, Canadian**  
17   **French version, kinesiophobia, behavioral medicine, psychometrics**

## 18 **1 Abstract**

19 **Background:** The Fear-Avoidance Components Scale (FACS) is a reliable and valid instrument  
20 widely used to assess fear-avoidance beliefs related to pain and disability. However, there is a scarcity  
21 of validated translations of the FACS in different cultural and linguistic contexts, including the French  
22 population. This study aimed to translate and validate the French version of the FACS (FACS-Fr/CF),  
23 examining its psychometric properties among French-speaking individuals.

24 **Methods:** A cross-cultural translation process – including forward translation, backward translation,  
25 expert committee review, and pre-testing – was conducted to develop the FACS-Fr/CF. The translated  
26 version was administered to a sample of French-speaking adults (n=55) with musculoskeletal  
27 conditions. Internal consistency (including confirmatory analyses of the 2 factors identified in the  
28 Serbian version), test-retest reliability and convergent validity were then assessed.

29 **Results:** The FACS-Fr/CF demonstrated high global internal consistency ( $\alpha=0.94$ , 95% CI: 0.91-0.96)  
30 as well as high internal consistency of the 2 factors identified in the Serbian version ( $\alpha=0.90$ , 95% CI:  
31 0.86-0.94 and  $\alpha=0.90$ , 95% CI: 0.85-0.94, respectively). Test-retest analysis revealed a moderate (close  
32 to high) reliability (ICC=0.89; 95% CI: 0.82-0.94 and  $r=0.89$ ;  $p<0.005$ ). Convergent validity was  
33 supported by significant correlations between the FACS-Fr/CF scores and the Tampa Scale for  
34 Kinesiophobia ( $r=0.82$ ;  $p < 0.005$ ), the Pain Catastrophizing Scale ( $r=0.72$ ;  $p < 0.005$ ) and the Hospital  
35 Anxiety and Depression Scale ( $r=0.66$ ;  $p < 0.005$ ).

36 **Conclusion:** The present study provides evidence for the cross-cultural translation and psychometric  
37 validation of the FACS-Fr/CF. The FACS-Fr/CF exhibits a high internal consistency, a moderate (close  
38 to high) test-retest reliability, and good construct validity, suggesting its utility in assessing fear-

39 avoidance beliefs in the French-speaking population. This validated tool can enhance the assessment  
40 and understanding of fear-avoidance behaviors and facilitate cross-cultural research in pain-related  
41 studies.

42

## 43 **2 Introduction**

44 The fear-avoidance (FA) model is proposed as a possible explanation for the transition from acute to  
45 chronic pain in some patients [1,2]. According to this model, individuals who perceive their pain as  
46 threatening and who catastrophize will tend to develop fear of pain, avoid regular activities, and  
47 monitor excessively bodily sensations [1,3,4]. These responses may precipitate physical  
48 deconditioning, limit the ability to work and to participate in recreational/familial activities, and foster  
49 depression [1,3,4].

50 Several patient-reported outcome (PRO) questionnaires have been developed to quantify FA related  
51 concepts, including the Tampa Scale for Kinesiophobia (TSK) [5], the Pain Anxiety Symptoms Scale  
52 (PASS) [6], the Pain Catastrophizing Scale (PCS) [7], and the Fear-Avoidance Beliefs Questionnaire  
53 (FABQ) [8]. However, the FA model has significantly evolved in recent years, and none of these  
54 questionnaires comprehensively examine all the cognitive, emotional, and behavioral components of  
55 the model [9]. Although they have been used in a substantial number of peer-reviewed published  
56 research, the psychometric properties of these tools (including construct validity and sensitivity to  
57 change) have sometimes been called into question [10], and some of their items have received criticism  
58 for being either too narrowly defined (only applicable to a single situation) or overly broad (too vague  
59 or subject to interpretation) [11]. Furthermore, while pain-related avoidance can occur due to fear of  
60 injury or reinjury, fear of increased pain, or an actual increase in pain, none of these questionnaires  
61 attempt to distinguish between these different cases [12].

62 In an attempt to address these shortcomings, Neblett et al. (2015) have developed the Fear Avoidance  
63 Component Scale (FACS) [9], which includes items from other published FA related measures (TSK,  
64 PASS, PCS, FABQ). The FACS also includes items based on the Injustice Experience Questionnaire  
65 (IEQ) [13], designed to assess the degree to which chronic pain sufferers feel injustice in relation to  
66 their pain. All FACS items were created to assess specific fear avoidance related beliefs and feelings  
67 about a person's painful medical condition, such as cognitive (pain catastrophizing), affective (pain-  
68 related fear and anxiety), and behavioral (avoidance) constructs [9]. In addition, six items (15 to 20)  
69 were developed to assess the specific types of activities and physical intensity of activities (from low  
70 to strenuous) that an individual avoids, and three items were developed to evaluate why the individual  
71 is avoiding these activities [9].

72 The original English version of the FACS has shown acceptable test-retest reliability ( $r=0.90-0.94$ ) as  
73 well as acceptable internal consistency (Cronbach  $\alpha=0.92$ ) [9]. The FACS has been translated and  
74 validated in several different languages. It has shown good psychometric properties in Serbian (test-  
75 retest reliability: ICC = 0.93; internal consistency: Cronbach  $\alpha =0.90$ ) [14], Spanish (convergent  
76 validity:  $r=0.41$ ; internal consistency: Cronbach  $\alpha=0.90-0.88$ ) [15], Gujarati (test-retest reliability:  
77 ICC=0.92; internal consistency: Cronbach  $\alpha=0.83$ ) [16], Dutch (internal consistency: Cronbach  
78  $\alpha=0.92$ ; test-retest reliability: ICC=0.92, CI 0.80-0.96) [17] and Turkish (internal consistency:  
79 Cronbach  $\alpha=0.815$ ; test-retest reliability: ICC=0.53-0.97).

80 There are currently about 321 million French speakers throughout the world. [18] However, a  
81 psychometrically validated French version of the FACS has not been made available to date. Clinical  
82 settings in French-speaking parts of the world – including France and Canada – could certainly benefit  
83 from a French version of this questionnaire. The aim of the current study was to translate the FACS

84 into a common French version, including dialects of France and Canadian French (FACS-Fr/CF), and  
85 to assess the psychometric properties of the translated questionnaire – including internal consistency,  
86 test-retest reliability, and construct validity.

## 87 **3 Materials and Methods**

88 The study was approved by the ethics committee of the Research Center on Aging du Centre Intégré  
89 Universitaire de Santé et de Services Sociaux de l'Estrie – Centre hospitalier universitaire de  
90 Sherbrooke (CIUSSS de l'Estrie CHUS) and registered on the ClinicalTrials website (NCT05217017).  
91 This study was conducted according to the principles expressed in the Declaration of Helsinki [19].

### 92 **3.1 Cross-cultural translation process**

93 The translation was performed using a six-step process according to the guidelines for the cross-cultural  
94 adaptation process written by the American Association of Orthopaedic Surgeons [20]. Initial  
95 translation, synthesis, back translation, expert committee, test of the prefinal version and submission  
96 of the document to the one of the original developers (RN) were performed. For the initial translation,  
97 two independent translators (ST and SW), whose mother tongue was French, translated the scale from  
98 English to French. A synthesized version of the two translated questionnaires was completed after  
99 discussion with the translator and research team. Two independent translators (BVD and AS), blinded  
100 to the original scale and whose native language was English, then translated the synthesized version  
101 back to English. An expert committee, comprised of the four translators and the research team,  
102 consolidated the prefinal version.

103 The content validity of the French FACS was pre-tested by 10 healthcare professionals (including  
104 physiotherapists, nurses, neuropsychiatrists, and orthopedic surgeons) and 20 individuals (healthy and  
105 pain patients), including 10 in Quebec (Canada), and 10 in France. All of them tested the prefinal  
106 version by completing the questionnaire and evaluating their understanding of each item. Each person  
107 was invited to report any interpretation difficulties and other observations about each test item [20].  
108 Based on participants' answers, only item 13 « *La douleur causée par mon état de santé est un signal*  
109 *d'alerte indiquant que quelque chose ne va pas du tout chez moi* » (“The pain from my medical  
110 condition is a warning signal that something is dangerously wrong with me”) turned into « *La douleur*  
111 *causée par mon état de santé est un signal d'alerte indiquant que quelque chose ne va pas du tout* »  
112 (“The pain from my medical condition is a warning signal that something is dangerously wrong”). This  
113 modification was made because of the end of the sentence (« *chez moi* »), suggesting a psychiatric  
114 disorder connotation in French. For the final step, the methods for obtaining the corrected French  
115 version (FACS-Fr/CF) were submitted to author (RN), one of the developers of the original FACS  
116 questionnaire (Fig 1). The cross-cultural translation process period ran from March 14, 2022 to March  
117 31, 2022.

118

119 **Fig 1. Flowchart of the development of the FACS-Fr/CF**

120

## 121 **3.2 Psychometric evaluation of the FACS-Fr/CF**

122 After cross-cultural adaptation and translation, the final version of the FACS-Fr/CF questionnaire was  
123 administered to a sample of participants suffering from chronic pain to evaluate internal consistency,

124 test-retest reliability, and convergent validity. This validation step was performed according to  
125 specialized pain medicine guidelines [21].

### 126 **3.2.1 Study population**

127 The target population for this study included patients with chronic musculoskeletal pain who spoke  
128 French as their first language and referred by a physician for a musculoskeletal condition at the hospital  
129 CIUSSS de l'Estrie-CHUS (convenience sampling method). The eligibility criteria were: 1) 18 years  
130 of age or older; 2) French as first language; and 3) chronic musculoskeletal pain for at least 3 months.  
131 Subjects were excluded if they were unable to consent, read or understand the study requirements (see  
132 Fig 2). The inclusion period ran from April 26, 2022 to November 1, 2022.

133

### 134 **Fig 2. Patient recruitment flowchart**

135

### 136 **3.2.2 Sample size**

137 To follow the Consensus-based Standards for the Selection of Health Measurement Instruments  
138 recommendations, we recruited 55 participants to meet the objectives of this study (50+10% loss) for  
139 the assessment of internal consistency, reliability and validity [22]. This percentage of loss to follow-  
140 up was based on the latest research at the CHUS orthopedic service and on a systematic review focused  
141 on orthopedic clinical services [23].



### 142 **3.2.3 Patient-reported outcome measures**

143 The Fear-Avoidance Components Scale (FACS) is a self-reported questionnaire used to  
144 comprehensively measure and identify FA in patients with painful medical conditions [24]. It brings  
145 together major FA components from earlier FA scales while seeking to address some of their  
146 inadequacies within the context of the most recent FA model [11]. This questionnaire consists of 20  
147 items on a Likert scale, ranging from 5 (completely agree) to 0 (completely disagree). The total score,  
148 which varies from 0 to 100, is calculated by adding the values of each item. The FACS includes 5  
149 severity levels with increasing severity, based upon quintiles: Subclinical (0 to 20), Mild (21 to 40),  
150 Moderate (41 to 60), Severe (61 to 80), and Extreme (81 to 100). Psychometric properties of the FACS  
151 show high internal consistency ( $\alpha = 0.92$ ) and high test-retest reliability ( $r = 0.90-0.94$ ,  $P < 0.01$ ) [24].  
152 The Serbian version of FACS found 2 different factors; factor 1 dealt with “general fear avoidance”  
153 and included items 1-14, while factor 2 was related to “types of activities that are avoided” and included  
154 items 15-20) [14].

155 The Tampa Scale for Kinesiophobia - Canadian French version (TSK-CF) is a self-reported  
156 questionnaire used to assess kinesiophobia. The TSK-CF has demonstrated good psychometric  
157 properties (Cronbach’s  $\alpha = 0.71$  and  $ICC > 0.7$ ) [25,26]. This questionnaire consists of 17-items  
158 evaluated on a Likert scale, ranging from 1 (strongly disagree) to 4 (strongly agree). The total score,  
159 which varies from 17 to 68, is calculated by adding the values of each item. There is no specific  
160 threshold to indicate a clinically disabling level of kinesiophobia [27].

161 The Pain Catastrophizing Scale - Canadian French version (PCS-CF) is a self-reported questionnaire  
162 used to measure catastrophic thoughts. The PCS-CF has shown good psychometric properties  
163 (Cronbach’s  $\alpha = 0.87$  and  $ICC > 0.7$ ) [28–31]. This questionnaire consists of 13 items, rated on a

164 Likert scale from 0 (not at all) to 4 (always), that can be categorized into three subscales: rumination  
165 (being unable to stop thinking about how much it hurts), amplification (exaggerating the threat value  
166 of pain sensations), and feelings of helplessness (feeling unable to cope with pain) [32]. The sum of  
167 the 13 items' values yields the final score, which ranges from 0 to 52. It has been suggested that a  
168 threshold score of 30 or higher can be used to identify people who have a clinically significant level of  
169 pain catastrophizing [33].

170 The Hospital Anxiety and Depression Scale - French Canadian version (HADS-FC) is a self-reported  
171 questionnaire used to measure the symptoms of anxiety and depression [34]. This questionnaire  
172 consists of 14 items intended to evaluate the severity of anxiety and depressive symptoms on two  
173 different subscales using a 4-point Likert-type scale (ranging between 0 and 3). Higher scores on the  
174 total scale indicate greater psychological distress. The internal consistency of the French version is  
175 good [35], with the depression subscale having Cronbach's alpha of 0.78 and the anxiety subscale  
176 having a Cronbach's alpha of 0.81.

### 177 **3.2.4 Study process and procedures**

178 Participants were recruited during an initial medical consultation visit at the orthopedic clinic of the  
179 CIUSSS de l'Estrie – CHUS. After the orthopedist completed the examination and consent to  
180 participate was obtained, patients were asked to complete a short sociodemographic questionnaire  
181 (including sex, age, physician's diagnosis, pain duration and academic level) using an online REDCap  
182 platform (REDCap 12.4.2 - © 2023 Vanderbilt University) [36]. Patients were then asked to fill out  
183 the four questionnaires (FACS-Fr/CF, TSK-CF, PCS-CF, HADS-CF). The questionnaires were  
184 completed online (REDCap) or on paper, depending on the participants' convenience or preference.

185 Then, seven days later, the patients were asked to complete the FACS-Fr/CF a second time, in the same  
186 way as the first time (online or paper). This timeframe was short enough to avoid significant clinical  
187 fluctuations from first completion and allow an appropriate test-retest evaluation [37].

### 188 **3.2.5 Statistical analysis**

189 Cronbach's alpha was used to assess the global internal consistency of the FACS-Fr/CF. We performed  
190 a global and confirmatory factors analysis (1 and 2) of the Serbian version. According to Wind *et al.*,  
191 2005,  $\alpha \geq 0.80$ ,  $\alpha \geq 0.70$  and  $\alpha < 0.70$  are considered as high, moderate and low, respectively [38].

192 The reliability was calculated with test-retest intraclass correlation coefficients (ICC) and Pearson  
193 correlation coefficients. According to Wind *et al.*, 2005,  $ICC \geq 0.90$ ,  $ICC \geq 0.75$  and  $ICC < 0.75$  are  
194 considered as high, moderate and low, respectively [38].

195 Convergent validity was assessed using Pearson's correlation coefficients, comparing the FACS-Fr/CF  
196 with the TSK-CF, the PCS-CF, and the HADS-FC. According to Wind *et al.*, 2005,  $r \geq 0.60$ ,  $r \geq 0.30$   
197 and  $r < 0.30$  are considered as high, moderate and low, respectively [38]. Considering the constructs  
198 of these different questionnaires, we expected to find stronger correlations with TSK-CF, followed by  
199 the PCF-CF and the HADS-FC.

200 All statistical analyses were performed using SPSS® (version 21); the significance level set at  $p=0.05$ .

## 201 **4 Results and discussion**

### 202 **4.1 Participants' characteristics**

203 Demographic information is provided in Table 1. Fifty-five (55) participants took part in the study,  
204 including 30 men (54.5%) and 25 women (45.5%). The average age for the total sample was  
205 51.15±16.47 years old. The average pain duration was 65.67±86.80 months. Pain-related medical  
206 diagnoses included arthrosis (n=12), tendinopathy (n=9), coxalgia (n=8), ligamentoplasty (n=6),  
207 labrum tear (n=5), tendon rupture (n=3), and low back pain (n=2). One subject each, for the remaining  
208 10 patients, were diagnosed with the following: stenosing flexor tenosynovitis, femur elongation,  
209 cervical surgery, elbow fracture, ankle pain, complex regional pain syndrome (CRPS), neuropathy of  
210 upper limbs, patellofemoral syndrome, Baker's cyst, crowned dens syndrome. The study ended on  
211 November 11, 2022 with the receipt of the last questionnaire.

212 **Table 1. Participant characteristics**

<b>Participant's characteristics</b>	<b>Total sample or mean (% or SD)</b>
<b>Age (years)</b>	51.15 (16.47)
<b>Sex</b>	30 men (54.5%) 25 women (45.5%)
<b>Diagnosis</b>	Arthrosis (12) Tendinopathy (9) Coxalgia (8) Ligamentoplasty (6) Labrum tear (5) Tendon rupture (3) Low back pain (2) Other (10)
<b>Pain duration (months)</b>	65.67 (86.80)
<b>FACS-Fr/CF (at first time)</b>	47.35 (22.85)
<b>PCF-CF</b>	19.40 (13.81)
<b>TSK-CF</b>	40.94 (9.71)
<b>HADS-FC</b>	13.49 (8.06)
<b>FACS-Fr/CF (retest 7 days later)</b>	45.43 (21.84)

213

## 214 **4.2 Internal consistency**

215 The global internal consistency of FACS-Fr/CF calculated by Cronbach's alpha was high ( $\alpha=0.94$ ,  
216 95% CI: 0.91-0.96). For factors 1 and 2, the Cronbach's alpha was high for both ( $\alpha=0.90$ , 95% CI:  
217 0.86-0.94 and  $\alpha=0.90$ , 95% CI: 0.85-0.94 respectively). The descriptive statistics and internal  
218 consistency for the FACS-Fr/CF items are shown in Table 2.

219 **Table 2. Internal consistency for the FACS-Fr/CF items**

FACS-Fr/CF items	Corrected total-item correlation	Cronbach's alpha if item deleted
1	.475	.934
2	.519	.934
3	.643	.931
4	.693	.930
5	.677	.931
6	.451	.935
7	.641	.931
8	.740	.930
9	.708	.930
10	.641	.931
11	.727	.930
12	.299	.938
13	.516	.934
14	.617	.932
15	.634	.932
16	.722	.930
17	.617	.932
18	.826	.928
19	.695	.930
20	.652	.931

220

### 221 **4.3 Reliability test retest**

222 Test-retest reliability of the FACS-Fr/CF was moderate, close to high (ICC=0.89; 95% CI: 0.82-0.94  
223 and  $r=0.89$ ;  $p<0.005$ ) [39].

## 224 4.4 Convergent validity

225 The convergent validity was assessed with Pearson's correlation coefficients (unilateral). The FACS-  
226 Fr/CF scores were highly correlated with scores on the TSK-CF ( $r=0.82$ ;  $p < 0.005$ ), PCS-CF ( $r=0.72$ ;  
227  $p < 0.005$ ) and HADS-FC ( $r=0.66$ ;  $p < 0.005$ ). All correlation coefficients are shown in Table 3.

228 **Table 3. Pearson's correlations (2-tailed) among PROs**

	FACS-Fr/CF	PCS-CF	TSK-CF	HADS-FC
FACS-Fr/CF	-			
PCS-CF	0.72***	-		
TSK-CF	0.82***	0.61***	-	
HADS-FC	0.66***	0.69***	0.66***	-

229 \*\*\* means  $p<0.005$

## 230 4.5 Discussion

231 This study aimed to establish and validate a cross cultural adaptation of the FACS questionnaire in  
232 French and Canadian French, using the guidelines for questionnaires in pain medicine proposed by  
233 Tsang, Royse and Terkawi [21]. Following a forward and backward translation process, and feedback  
234 from 10 healthcare professionals and 20 patients, a final version of the FACS-Fr/CF was established.  
235 The psychometric properties were then assessed in a sample of 55 chronic pain patients who completed  
236 the final FACS-Fr/CF on 2 occasions at a 2-week interval, as well as 3 other questionnaires, which  
237 assessed related constructs.

238 Global internal consistency of FACS-Fr/CF was high ( $\alpha=0.94$ ,) and comparable to the original FACS  
239 ( $\alpha=0.92$ ) [24]. The internal consistency of the 2 factors identified previously in the Serbian version was  
240 also high, despite the relatively small number of items for factor 2. Test-retest reliability of the FACS-  
241 Fr/CF was moderate, very close to high. These values are consistent with those obtained for the original  
242 version ( $r = 0.90-0.94$ ,  $P < 0.01$ ) [24].

243 For convergent validity, we assessed the relationship between the scores of the FACS-Fr/CF, the TSK-  
244 CF, the PCS-CF and the HADS-FC. A previous study with the Spanish and Turkish versions of the  
245 FACS found a moderate and strong correlation with the Spanish and Turkish version of the TSK, with  
246 a coefficient  $r=0.39$  and  $r=0.56$  respectively [40,41]. In the present study, we observed a high  
247 correlation between the FACS-Fr/CF and the TSK-CF ( $r=0.82$ ). As expected, the correlation was  
248 higher with the TSK-CF, compared to the PCS-CF ( $r=0.72$ ) and the HADS-FC ( $r=0.66$ ), suggesting  
249 that the constructs underlying the FACS and TSK are particularly close [24]. This finding is perhaps  
250 not so surprising when we bear in mind that some of the items from the FACS were borrowed directly  
251 from the TSK [9].

252 We also examined the convergent validity of FACS, by assessing its relationship with the PCS. In  
253 previous studies, the Spanish version showed a moderate correlation with the PCS ( $r=0.49$  to  $0.53$ )  
254 [40,42], and the Serbian and Turkish versions showed a high correlation ( $r=0.77$  and  $r=0.68$   
255 respectively) [14,41]. The high correlation between the FACS-Fr/CF and PCS-CF ( $r=0.72$ ;  $p < 0.005$ )  
256 was very close to the Serbian and Turkish versions.

257 FA is frequently associated with anxiety [43] and depression [44]. Though anxiety and depression are  
258 related to FA, these constructs are somewhat different [45]. The association between FACS-Fr/CF and

259 HADS-FC scores was therefore expected to be weaker than those observed between the FACS-Fr/CF  
260 and TSK-CF, and between the FACS-Fr-CF and PCS-CF.

261 All in all, the pattern of convergent validity results in the present study is consistent with the a priori  
262 assumptions that postulated a higher correlation coefficient between FACS-Fr/CF and TSK-CF scores  
263 [46,47], followed by the PCS-CF (with symptoms of helplessness, rumination and magnification being  
264 an important component of the FA model [48]) and by the HADS-FC [49].

265 This study has a number of strengths and limitations. One strength was that the American Association  
266 of Orthopedic Surgeons and the Consensus-based Standards for the Selection of Health Measurement  
267 Instruments recommendations were followed in the cross-cultural adaptation and validation process.  
268 Furthermore, the FACS-Fr/CF was developed as a standardized version, accommodating two distinct  
269 French language dialects (France and Canada). As a result, it has potential for broad applicability across  
270 diverse French-speaking regions, worldwide. However, it is important to exercise caution when using  
271 the instrument in specific contexts, as further validation studies may be necessary to ensure its  
272 appropriateness for local linguistic variations and cultural nuances.

273 An important limitation of this study concerns recruitment, as the 55 patients included in the sample  
274 were recruited from a single hospital – a situation that may raise questions about the generalizability  
275 of the results. However, it is important to note that this limitation may be partially mitigated by the  
276 important variability observed among the pain conditions encompassed within the sample.  
277 Nonetheless, extrapolating the results to broader chronic pain populations, outside the specific context  
278 of the study, should be done with caution.

279



## 280 **5 Conclusions**

281 This is the first translation, intercultural adaptation and validation study of the FACS in French version,  
282 including dialects of France and Canadian French. The FACS-Fr/CF showed a high global internal  
283 consistency and moderate (very close to high) test-retest reliability. The convergent validity of the  
284 FACS-Fr/CF was demonstrated by positive correlations with TSK, PCS and HADS. This work  
285 provides an important basis for the future use of the FACS-Fr/CF in assessing fear-avoidance beliefs  
286 in various French-speaking cultural contexts.

## 287 **6 Supporting information**

288 **S1 File. Fear-avoidance Components Scale, French/Canadian French version (FACS-Fr/CF)**

289

## 290 **7 Conflict of Interest**

291 The authors declare that the research was conducted in the absence of any commercial or financial  
292 relationships that could be construed as a potential conflict of interest.

## 293 **8 Funding**

294 This study was funded by *Fond de Recherche et Enseignement en Orthopédie de Sherbrooke* (FREOS).  
295 GL received salary support by the Fonds de recherche du Québec – Santé (FRQS).

## 296 **9 Acknowledgments**

297 We would especially like to thank Doctor Stéphane Ricard and the orthopedic service of CIUSSS de  
298 l'Estrie-CHUS for recruiting participants, as well as Professor Cynthia Gagnon for her help with the  
299 translation process.

## 300 **10 References**

- 301 1. Vlaeyen JWS, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain:  
302 a state of the art. *Pain*. 2000/04/27 ed. 2000;85: 317–332. doi:10.1016/s0304-3959(99)00242-0
- 303 2. Lethem J, Slade PD, Troup JD, Bentley G. Outline of a Fear-Avoidance Model of exaggerated  
304 pain perception--I. *Behav Res Ther*. 1983;21: 401–408. doi:10.1016/0005-7967(83)90009-8
- 305 3. Vlaeyen JWS, Kole-Snijders AMJ, Rotteveel AM, Ruesink R, Heuts PHTG. The role of fear of  
306 movement/(re)injury in pain disability. *J Occup Rehab*. 1995;5: 235–252.  
307 doi:10.1007/BF02109988
- 308 4. Vlaeyen JW, Linton SJ. Fear-avoidance model of chronic musculoskeletal pain: 12 years on. *Pain*.  
309 2012;153: 1144–1147.
- 310 5. Miller RP, Kori SH, Todd DD. The Tampa Scale: a measure of kinesisophobia. *The Clinical journal*  
311 *of pain*. 1991;7: 51.
- 312 6. McCracken LM, Zayfert C, Gross RT. The Pain Anxiety Symptoms Scale: development and  
313 validation of a scale to measure fear of pain. *Pain*. 1992;50: 67–73. doi:10.1016/0304-  
314 3959(92)90113-P

- 315 7. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development and validation.  
316 Psychological Assessment. 1995;7: 524–532. doi:10.1037//1040-3590.7.4.524
- 317 8. Waddell G, Newton M, Henderson I, Somerville D, Main CJ. A Fear-Avoidance Beliefs  
318 Questionnaire (FABQ) and the role of fear-avoidance beliefs in chronic low back pain and  
319 disability. Pain. 1993;52: 157–168. doi:10.1016/0304-3959(93)90127-B
- 320 9. Neblett R, Mayer TG, Hartzell MM, Williams MJ, Gatchel RJ. The Fear-avoidance Components  
321 Scale (FACS): Development and Psychometric Evaluation of a New Measure of Pain-related Fear  
322 Avoidance. Pain Pract. 2015;16: 435–450. doi:10.1111/papr.12333
- 323 10. Lundberg M, Grimby-Ekman A, Verbunt J, Simmonds MJ. Pain-related fear: a critical review of  
324 the related measures. Pain Res Treat. 2011;2011: 494196. doi:10.1155/2011/494196
- 325 11. Pincus T, Smeets RJEM, Simmonds MJ, Sullivan MJL. The fear avoidance model disentangled:  
326 Improving the clinical utility of the fear avoidance model. Clin J Pain. 2010;26: 739–746.  
327 doi:10.1097/AJP.0b013e3181f15d45
- 328 12. Rainville J, Smeets RJEM, Bendix T, Tveito TH, Poiraudreau S, Indahl AJ. Fear-avoidance beliefs  
329 and pain avoidance in low back pain--translating research into clinical practice. Spine J. 2011;11:  
330 895–903. doi:10.1016/j.spinee.2011.08.006
- 331 13. Sullivan MJ, Adams H, Horan S, Maher D, Boland D, Gross R. The role of perceived injustice in  
332 the experience of chronic pain and disability: scale development and validation. J Occup Rehabil.  
333 2008/06/10 ed. 2008;18: 249–61. doi:10.1007/s10926-008-9140-5

- 334 14. Knezevic A, Neblett R, Gatchel RJ, Jeremic-Knezevic M, Bugarski-Ignjatovic V, Tomasevic-  
335 Todorovic S, et al. Psychometric validation of the Serbian version of the Fear Avoidance  
336 Component Scale (FACS). PLoS One. 2018;13: e0204311. doi:10.1371/journal.pone.0204311
- 337 15. Cuesta-Vargas AI, Neblett R, Gatchel RJ, Roldán-Jiménez C. Cross-cultural adaptation and  
338 validity of the Spanish fear-avoidance components scale and clinical implications in primary care.  
339 BMC Fam Pract. 2020;21: 44. doi:10.1186/s12875-020-01116-x
- 340 16. Bid DD, Neblett R, Alagappan TR, Patel CJ, Patel KN, Patel RL, et al. Cross-cultural adaptation,  
341 reliability, and validity of the Gujarati fear-avoidance components scale. Physiotherapy-The  
342 Journal of Indian Association of Physiotherapists. 2020;14: 98.
- 343 17. De Baets L, Sergooris A, Neblett R, Matheve T, Mingels S, Van Goethem A, et al. The  
344 development and measurement properties of the Dutch version of the fear-avoidance components  
345 scale (FACS-D) in persons with chronic musculoskeletal pain. Scand J Pain. 2022.  
346 doi:10.1515/sjpain-2022-0046
- 347 18. Organisation internationale de la Francophonie. La langue française dans le monde, Synthèse  
348 2022. Consulted on : 2022-10-07. Available at:  
349 [https://www.francophonie.org/sites/default/files/2022-](https://www.francophonie.org/sites/default/files/2022-03/Synthese_La_langue_francaise_dans_le_monde_2022.pdf)  
350 [03/Synthese\\_La\\_langue\\_francaise\\_dans\\_le\\_monde\\_2022.pdf](https://www.francophonie.org/sites/default/files/2022-03/Synthese_La_langue_francaise_dans_le_monde_2022.pdf). Gallimard. 2022.
- 351 19. WMA - The World Medical Association-Déclaration d'Helsinki de L'AMM – Principes éthiques  
352 applicables à la recherche médicale impliquant des êtres humains. [cited 24 Nov 2020]. Available:  
353 [https://www.wma.net/fr/policies-post/declaration-dhelsinki-de-lamm-principes-ethiques-](https://www.wma.net/fr/policies-post/declaration-dhelsinki-de-lamm-principes-ethiques-applicables-a-la-recherche-medicale-impliquant-des-etres-humains/)  
354 [applicables-a-la-recherche-medicale-impliquant-des-etres-humains/](https://www.wma.net/fr/policies-post/declaration-dhelsinki-de-lamm-principes-ethiques-applicables-a-la-recherche-medicale-impliquant-des-etres-humains/)

- 355 20. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural  
356 adaptation of self-report measures. *Spine (Phila Pa 1976)*. 2000;25: 3186–3191.  
357 doi:10.1097/00007632-200012150-00014
- 358 21. Tsang S, Royse CF, Terkawi AS. Guidelines for developing, translating, and validating a  
359 questionnaire in perioperative and pain medicine. *Saudi J Anaesth*. 2017;11: S80–S89.  
360 doi:10.4103/sja.SJA\_203\_17
- 361 22. Mokkink LB, de Vet HCW, Prinsen C a. C, Patrick DL, Alonso J, Bouter LM, et al. COSMIN  
362 Risk of Bias checklist for systematic reviews of Patient-Reported Outcome Measures. *Qual Life*  
363 *Res*. 2018;27: 1171–1179. doi:10.1007/s11136-017-1765-4
- 364 23. Somerson JS, Bartush KC, Shroff JB, Bhandari M, Zelle BA. Loss to follow-up in orthopaedic  
365 clinical trials: a systematic review. *Int Orthop*. 2016;40: 2213–2219. doi:10.1007/s00264-016-  
366 3212-5
- 367 24. Neblett R, Mayer TG, Hartzell MM, Williams MJ, Gatchel RJ. The Fear-avoidance Components  
368 Scale (FACS): Development and Psychometric Evaluation of a New Measure of Pain-related Fear  
369 Avoidance. *Pain Pract*. 2016;16: 435–450. doi:10.1111/papr.12333
- 370 25. French DJ, Roach PJ, Mayes S. Peur du mouvement chez des accidentés du travail: L'Échelle de  
371 Kinésiophobie de Tampa (EKT). [Fear of movement in injured workers: The Tampa Scale of  
372 Kinesiophobia.]. *Canadian Journal of Behavioural Science / Revue canadienne des sciences du*  
373 *comportement*. 2002;34: 28–33. doi:10.1037/h0087152
- 374 26. Weermeijer JD, Meulders A. Clinimetrics: Tampa Scale for Kinesiophobia. *Journal of*  
375 *Physiotherapy*. 2018;64: 126. doi:10.1016/j.jphys.2018.01.001

- 376 27. Vlaeyen JW, Kole-Snijders AM, Boeren RG, van Eek H. Fear of movement/(re)injury in chronic  
377 low back pain and its relation to behavioral performance. *Pain*. 1995;62: 363–372.
- 378 28. French DJ, Noël M, Vigneau F, French JA, Cyr CP, Evans RT. L'Échelle de dramatisation face  
379 à la douleur PCS-CF: Adaptation canadienne en langue française de l'échelle «Pain  
380 Catastrophizing Scale». [PCS-CF: A French-language, French-Canadian adaptation of the Pain  
381 Catastrophizing Scale.]. *Canadian Journal of Behavioural Science / Revue canadienne des  
382 sciences du comportement*. 2005;37: 181–192. doi:10.1037/h0087255
- 383 29. Osman A, Barrios FX, Kopper BA, Hauptmann W, Jones J, O'Neill E. Factor structure, reliability,  
384 and validity of the Pain Catastrophizing Scale. *Journal of Behavioral Medicine*. 1997;20: 589–  
385 605. doi:10.1023/A:1025570508954
- 386 30. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development and validation.  
387 *Psychological Assessment*. 1995;7: 524–532. doi:10.1037//1040-3590.7.4.524
- 388 31. Tremblay I, Beaulieu Y, Bernier A, Crombez G, Laliberté S, Thibault P, et al. Pain  
389 Catastrophizing Scale for Francophone Adolescents: a preliminary validation. *Pain Res Manag*.  
390 2008;13: 19–24.
- 391 32. Osman A, Barrios FX, Gutierrez PM, Kopper BA, Merrifield T, Grittmann L. The Pain  
392 Catastrophizing Scale: further psychometric evaluation with adult samples. *J Behav Med*.  
393 2000;23: 351–365.
- 394 33. Sullivan MJ. *The Pain Catastrophizing Scale*. 2009; 36.

- 395 34. Roberge P, Doré I, Menear M, Chartrand É, Ciampi A, Duhoux A, et al. A psychometric  
396 evaluation of the French Canadian version of the Hospital Anxiety and Depression Scale in a  
397 large primary care population. *Journal of Affective Disorders*. 2013;147: 171–179.  
398 doi:10.1016/j.jad.2012.10.029
- 399 35. Bocéréan C, Dupret E. A validation study of the Hospital Anxiety and Depression Scale (HADS)  
400 in a large sample of French employees. *BMC Psychiatry*. 2014;14: 354. doi:10.1186/s12888-014-  
401 0354-0
- 402 36. Garcia KKS, Abrahão AA. Research Development Using REDCap Software. *Healthc Inform*  
403 *Res*. 2021;27: 341–349. doi:10.4258/hir.2021.27.4.341
- 404 37. Streiner DL, Norman GR, Cairney J. *Health measurement scales: A practical guide to their*  
405 *development and use*, 5th ed. New York, NY, US: Oxford University Press; 2015. pp. xiii, 399.  
406 doi:10.1093/med/9780199685219.001.0001
- 407 38. Wind H, Gouttebauge V, Kuijer PPFM, Frings-Dresen MHW. Assessment of functional capacity  
408 of the musculoskeletal system in the context of work, daily living, and sport: a systematic review.  
409 *J Occup Rehabil*. 2005;15: 253–272. doi:10.1007/s10926-005-1223-y
- 410 39. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for  
411 Reliability Research. *J Chiropr Med*. 2016;15: 155–163. doi:10.1016/j.jcm.2016.02.012
- 412 40. Gutiérrez-Sánchez D, Roldán-Jiménez C, Pajares B, Alba E, Cuesta-Vargas AI. Validity and  
413 reliability of the Spanish fear-avoidance components scale in breast cancer survivors. *European*  
414 *Journal of Cancer Care*. 2021;30: e13506. doi:10.1111/ecc.13506

- 415 41. Turan K, Sarı Z, Özden F. Psychometric properties of the Turkish version of the fear avoidance  
416 components scale in patients with chronic pain related to musculoskeletal disorders. *Wien Klin*  
417 *Wochenschr.* 2023. doi:10.1007/s00508-023-02224-1
- 418 42. Pérez-Cruzado D, Roldan-Jimenez C, Iglesias-Campos M, Pajares B, Alba E, Cuesta-Vargas A.  
419 Validation of pain catastrophizing scale on breast cancer survivor. *Pain Pract.* 2022;22: 711–717.  
420 doi:10.1111/papr.13163
- 421 43. Pincus T, Vogel S, Burton AK, Santos R, Field AP. Fear avoidance and prognosis in back pain:  
422 a systematic review and synthesis of current evidence. *Arthritis Rheum.* 2006;54: 3999–4010.  
423 doi:10.1002/art.22273
- 424 44. Brindisino F, Garzonio F, DI Giacomo G, Pellegrino R, Olds M, Ristori D. Depression, fear of  
425 re-injury and kinesiophobia resulted in worse pain, quality of life, function, and level of return to  
426 sport in patients with shoulder instability. A systematic review. *J Sports Med Phys Fitness.* 2022.  
427 doi:10.23736/S0022-4707.22.14319-7
- 428 45. Sloan E, Hall K, Moulding R, Bryce S, Mildred H, Staiger PK. Emotion regulation as a  
429 transdiagnostic treatment construct across anxiety, depression, substance, eating and borderline  
430 personality disorders: A systematic review. *Clin Psychol Rev.* 2017;57: 141–163.  
431 doi:10.1016/j.cpr.2017.09.002
- 432 46. Abma IL, Rovers M, van der Wees PJ. Appraising convergent validity of patient-reported  
433 outcome measures in systematic reviews: constructing hypotheses and interpreting outcomes.  
434 *BMC Res Notes.* 2016;9: 226. doi:10.1186/s13104-016-2034-2



- 435 47. French DJ, France CR, Vigneau F, French JA, Evans RT. Fear of movement/(re)injury in chronic  
436 pain: a psychometric assessment of the original English version of the Tampa scale for  
437 kinesiophobia (TSK). *Pain*. 2007;127: 42–51. doi:10.1016/j.pain.2006.07.016
- 438 48. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development and validation.  
439 *Psychological Assessment*. 1995;7: 524–532. doi:10.1037//1040-3590.7.4.524
- 440 49. Djukanovic I, Carlsson J, Årestedt K. Is the Hospital Anxiety and Depression Scale (HADS) a  
441 valid measure in a general population 65–80 years old? A psychometric evaluation study. *Health*  
442 *Qual Life Outcomes*. 2017;15: 193. doi:10.1186/s12955-017-0759-9
- 443
- 444

Original Fear-Avoidance Components Scale (FACS)  
English version

medRxiv preprint doi: <https://doi.org/10.1101/2023.07.07.23292355>; this version posted July 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

*Translator 1*

*Translator 2*

FACS-Fr/CF T1

FACS-Fr/CF T2

*Comparison and discussion*

FACS-Fr/CF T1-2

*Back Translator 1*

*Back Translator 2*

FACS BT1

FACS BT2

*Comparison to the original FACS  
(native English speaker)*

Evaluation of FACS-Fr/CF  
by patients and developer

Final Fear-Avoidance Components Scale  
French/Canadian-French version (FACS-Fr/CF)

Fig1




Fig2